Trials / Unknown
UnknownNCT04412889
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM
A Study of B-Cell Maturation Antigen/Cluster of Differentiation 19 Dual-Target Chimeric Antigen Receptor T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Hebei Yanda Ludaopei Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of BCMA/CD19 dual-target CAR-T cell immunotherapy in relapsed or refractory MM. The study will include 18 subjects to receive BCMA/CD19 dual-target CAR-T cell immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BCMA/CD19 dual-target CAR-T cell immunotherapy | The intervention is a CAR-T cell immunotherapy targeted CD19 and BCMA. The dosage ranges from 2×10\^5 to 1×10\^6 CAR+T/Kg. |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2020-06-02
- Last updated
- 2020-06-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04412889. Inclusion in this directory is not an endorsement.